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The transplantability of human malignancies in
athymic nu/nu mice varies greatly and for some
tumour types the establishment of serially trans-
plantable tumour lines has proven to be difficult
(Giovanella et al., 1978; Fogh et al., 1980). The take
rate and tumour growth do not only depend on
properties ofthe tumour type, but other factors have
also been implicated, such as the selected mouse
strain (Maruo et al., 1982), the site of implantation
(Kyriazis & Kyriazis, 1980) and the hormonal status
of the mouse (Leung & Shiu, 1981).
In the nude mouse with T cell immune
deficiency, the residual immune system may be a
major mechanism in the inhibition of tumour
transplantability. The higher phagocytic activity of
macrophages that can be observed in these animals
as a possible mechanism to overcome the immuno-
logical defect, was shown to play a role in the
rejection of heterologous tumour tissue (Kopper et
al., 1980, 1981; Vetvicka et al., 1984; Sharp &
Colston, 1984). In addition, nude mice are known
to possess a higher natural killer (NK) cell activity
as compared to normal mice (Herberman et al.,
1975). NK cell activity appears to be an important
mechanism to prevent tumour cell proliferation.
For instance, the number of NK cells in mice
correlates inversely with the number of experi-
mental pulmonary metastases (Hanna et al., 1982;
Talmadge et al., 1980).
In our laboratory the transplantation of ovarian
cancer tissue from patients into nude mice resulted
in a take rate of 32% with 11% established tumour
lines (Boven, 1986). These figures correspond with
data obtained in ovarian cancer by other
investigators (Kullander et al., 1978; Teufel et al.,
1981; Friedlander et al., (1985). Furthermore, the
take rate in subsequent passages does not always
reach 100% and may vary greatly. In order to
improve the take rate and growth of human
ovarian cancer xenografts, we pretreated our mice
with cyclophosphamide (CY) in an attempt to
reduce the NK cell activity. The effect of CY on
the spontaneous NK cell activity in our mice was
also mneasured.
Female 6-week-old BIO LP/Cpb nude (nu/nu)
mice, were purchased from TNO, Zeist, NL. The
animals were maintained in cages with paper filter
covers. Cages, covers, bedding, food, and water
were sterilized and changed weekly. Animal
handling was done in a laminar down-flow hood.
Seven tumour lines of ovarian cancer origin and
differing in histological subtype and growth rate
were studied (Table I). Tumour lines FKo, FCo,
and FMa were kindly provided by Dr W. Kleine,
Table I Human ovarian cancer lines
Tumour line Histology
Ov.Ri(C) moderately differentiated serous adenocarcinoma
Ov.He moderately differentiated mucinous adenocarcinoma
FKo moderately differentiated serous adenocarcinoma
FCo poorly differentiated clear cell carcinoma
Ov.Gl poorly differentiated serous adenocarcinoma
Ov.Sl moderately differentiated serous adenocarcinoma
FMa poorly differentiated endometrioid adenocarcinoma
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Albert-Ludwigs University, Freiburg, FRG, while
the other lines were established in our laboratory.
Tumour fragments of 3 x 2 x 2mm were implanted
s.c. in both flanks in the thoracic region in a series
of8-week-old animals. Tumours were measured once
a week with vernier calipers by the same observer.
The tumour volume was expressed by the equation
length x width x height x 0.5 in mm3. A tumour
take was scored, if the nodule reached at least a
volume of 50mm3. Volume doubling time was
calculated as the number of days for the tumour
to grow from 50mm3 to 100mm3 (TD50-100). The
latency period (Tv,5) was the number of days
from implantation until a volume of 50mm3 was
reached.
CY (ASTA Werke, Bielefeld, FRG) was dis-
solved in distilled water at a concentration of
20mgml-1 prior before use. Twelve animals were
randomly divided into a treatment group and a
control each of 5 to 7 mice. Treatment consisted of
a single dose of CY 100mgkg-1 i.p. 24h before
tumour implantation.
The cytotoxic capacity of nude mouse NK cells
was performed according to Romijn (1985). Briefly,
effector cells were prepared as single cells from
mouse spleens at three different concentrations.
YAC-1 target cells were labelled with 200pCi
Na251CrO4 solution per 1 x 106 cells for 1 h at 37°C
(51Cr at a specific activity of 50-400mCimg-1 was
obtained from Amersham, Buckinghamshire, UK).
Viable target cells at a number of 1 x 104 in 0.1 ml
culture medium were incubated with the effector
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cells in 0.1 ml culture medium at three different
ratios 1: 25, 1: 50 and 1: 100 in 96-well round-
bottom microtiter plates for 4h at 37°C. After
incubation the plates were centrifuged for 10min at
150 g and the release of 51Cr in the supernatants
determined by counting radioactivity in a gamma
counter. The degree of cytotoxicity was calculated
according to the following formula:
experimental release -
specific spontaneous release
release maximum release -
spontaneous release
All tests were done in quadruplicate with four
control and four CY-treated mice, 8 weeks of age.
In order to analyze the differences between the
tumour take rate in treated and control mice the x2
test was applied to each of the tumour lines. The
statistical differences in the NK cell cytotoxicity
assay were evaluated using Student's t test.
In serial transplantation the take rate in the seven
human ovarian cancer lines was always below
100% (Table II). In four of them, Ov.He, FCo,
Ov.Sl, and FMa, the take rate was frequently below
50%. After CY administration at a dose of
100mgkg-1 i.p. 24h before tumour implantation,
the transplantability increased in Ov.He, FKo,
FCo, and Ov.Sl. These results could be repeated
and were significantly different from the take rate
in control animals (Figure 1). The slight improve-
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Figure 1 Take rate (%) obtained in seven human tumour lines transplanted either in CY-pretreated mice or in
control mice. Statistical analysis was performed with the x2 test.ENHANCED TRANSPLANTABILITY BY CYCLOPHOSPHAMIDE 333
Table II Effect of cyclophosphamide pretreatment on the take rate, latency
period and tumour doubling time in seven human ovarian cancer lines in
nude mice
CY pretreatment Control
Tumour Take Take
line Passage ratea Tv50 TD50-I10 ratea TV50 TDSOlo1
Ov.Ri(C) 6 90 29+ 5 11+ 3 100 33+ 8 11+ 3
7 100 31+ 7 10+ 4 75 36+ 4 8+ 4
Ov.He 10 100 56+17 8+ 6 83 58+18 13+ 6
12 92 27+ 5 8+ 7 25 43+27 14+12
13 100 16+ 5 4+ 2 20 16+ 5 5+ 5
15 75 36+ 4 9+ 5 50 26+15 10+ 3
16 58 27+ 3 7+ 4 25 26+ 2 3+ 1
FKo 3 100 26+ 3 14+ 5 40 36+ 9 14+11
4 93 22+ 9 8+ 7 50 22+ 8 8+ 6
5 100 22+ 7 7+ 4 50 23+ 2 10+ 3
6 100 27+ 9 9+ 4 67 21+ 2 14+ 3
7 100 25+ 4 7+ 2 60 24+ 5 9+ 3
FCo 3 67 46+12 14+ 6 0
3 50 34+ 3 7+ 3 88 38+ 7 13+12
4 70 44+14 18+10 60 38+27 17+ 5
5 83 47+ 9 15+14 25 56 18
6 92 47+14 14+ 7 38 28+ 3 8+ 5
Ov.Gl 10 67 40+10 12+ 5 75 60+ 13 21+11
12 100 38+ 6 18+ 1 33 59+ 8 19+ 8
Ov.Sl 3 40 24+ 9 9+ 5 0
4 92 63+14 21+12 38 54+12 19+ 5
6 83 38+15 18+ 7 67 41+25 13+ 4
FMa 5 21 33+ 6 17+ 4 20 37+ 4 14+ 5
5 42 47+17 6+ 2 20 50+ 5 5+ 3
CY was injected i.p. at a dose of 100mgkg-1 24h before tumour
implantation. The take rate refers to the number of nodules growing
beyond 50mm3 as a apercentage of the tumours that could be expected. The
latency period (TV50) is the number of days (±s.d.) fronm transplantation to
50mm3 and the tumour doubling time is the number of days (±s.d.) from
50mm3 to 100mm3.
ment of the take rate in tumour lines Ov.Ri(C)
FMa, and Ov.Gl was not significant. CY did not
cause toxicity in the mice or inhibition of tumour
transplantability. The latency period and the
doubling time of the respective tumour lines were
not affected.
The spontaneous NK cell cytotoxicity of isolated
spleen cells from control and CY-treated nude mice
was measured on YAC-1 target cells. Figure 2
shows that an effector-to-target ratio of 50: 1 and
100:1 induced a definite cytotoxic effect, which was
significantly lower in treated mice with values of
7.6% and 11.6% than in control mice with values
of 15.1% and 27.6% (P<0.02 and P<0.01
respectively).
The significant increase of the take rate in four
of seven ovarian cancer lines in CY-pretreated mice
in combination with the observed reduced NK cell
activity in these animals strongly suggests that some
human ovarian cancer xenografts are susceptible to
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Figure 2 NK cell mediated cytotoxicity of isolated
spleen cells from CY-pretreated mice and control mice
against 51Cr-labelled YAC-1 target cells.
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NK cell-mediated cytotoxicity. Because we are
employing our tumour lines for chemotherapy
studies (Boven et al., 1985a,b), it is of the utmost
importance to optimise the number of tumour-
bearing animals to achieve reliable results.
CY is known as an alkylating agent with anti-
tumour and immunosuppressive properties. The
drug is a potent inhibitor of spontaneous NK cell
activity in both normal and nude mice (Djeu et al.,
1979; Riccardi et al., 1981). In two separate studies
it was shown that in normal mice with a low NK
cell activity upon CY treatment, the formation of
experimental pulmonary metastases was markedly
enhanced (Hanna & Fidler, 1980; Vollmer &
Conley, 1984). The NK cell activity in nude mice
does not only vary with age and health of the
animals (Hanna et al., 1982), but also with the
nude mouse strain (Herberman et al., 1975).
Recently, Fodstad et al. (1984) reported on the
lack of correlation between NK cell activity and
tumour growth control in nude mice of varying
immune-deficient backgrounds. These data are
suggestive for a complex mechanism in the
regulation of the immune response in nudes. In
addition, Romijn (1985) demonstrates that tumour
lines with a relative insensitivity to NK cells also
had a better growth pattern in young nude mice.
Besides reduction of NK cell activity CY is known
to effectively suppress other cell-mediated immuno-
logic reactions in man and animals (Hunninghake
& Fauci, 1976). Whether these immunological
mechanisms play a role in the rejection of human
tumour tissue in the nude mouse has yet to be
clarified.
Because of the short plasma half-life of 5 to 6h
(Bagely et al., 1973), CY cannot be expected to
exert its cytotoxic action on tumour tissue
fragments implanted one day after administration.
Moreover, CY pretreatment did not affect the
latency period and the doubling time of our tumour
lines. These observations are of importance, if
tumour lines are being used for chemotherapy
studies.
From our studies it can be concluded that CY
pretreatment can increase the take rate of several
human ovarian cancer lines. CY suppressed NK
cell activity in our nude mice, which may be an
explanation for the enhanced transplantability.
Further investigations are warranted, to determine
the effect of CY on the success rate of primary
transplants of ovarian cancer.
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